UVX, Inc. and Research Nova Scotia Commence $2.8M Clinical Trial to Harness Far UV-C Technology to Combat Healthcare-Acquired Infections
Ushio is excited to share news regarding a Far UV-C clinical trial currently underway in Canada. Research NovaScotia is conducting a $2.8M study at three long-term care facilities in NovaScotia with the support of Ushio’s Care222 partner, UVX. This randomized double-blind placebo control trial is the first of its kind using filtered Far UV-C globally. Among other objectives, the clinical trial will investigate skin safety, eye safety, and effectiveness of Far UV-C in mitigating infection rates of high-risk senior care residents.
About Ushio America, Inc.
The Care222 standard character mark and stylized logo mark (“the Care222 Marks”) are registered trademarks of Ushio America, Inc., in the United States, European Union, United Kingdom, and Japan. The Care222 Marks are otherwise trademarks of Ushio America, Inc. or Ushio Inc.